 |
|
|
| |
144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years
|
| |
| |
CROI 2020 March 9
Reported by Jules Levin
Anthony Mills,1Samir K. Gupta,2Cynthia Brinson,3Kimberly Workowski,4Amanda Clarke,5Andrea Antinori,6Jeffrey L. Stephens,7Ellen Koenig,8Jose R. Arribas,9David M. Asmuth,10Douglas Ward,11Jürgen K. Rockstroh,12Hailin Huang,13Hal Martin,13Diana M. Brainard13
1Men’s Health Foundation, West Hollywood, CA; 2Indiana University School of Medicine, Indianapolis, IN; 3Central Texas Clinical Research, Austin, TX; 4Emory University, Atlanta, GA; 5Brighton & Sussex University Hospitals NHS Trust, Brighton, UK; 6Lazzaro Spallanzani Istituto Nazionale Malattie Infettive, Roma, Italy; 7Mercer University, Macon, GA; 8Instituto Dominicano de Estudios Virológicos, Santo Domingo, Dominican Republic; 9Hospital Universitario La Paz, Madrid, Spain; 10University of California, Davis; 11Dupont Circle Physicians Group, Washington, DC; 12Universitätsklinikums Bonn, Germany; 13Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
